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Abstract
Background: Family history is one of the risk factors for pancreatic cancer. It is suggested that patients with
pancreatic cancer who have a familial history harbor germline pathogenic variants of BRCA1 and/or BRCA2 (BRCA1/
2), PALB2, or ATM. Recently, some germline variants of familial pancreatic cancers (FPCs), including PALB2, have been
detected. Several countries, including Japan, perform screening workups and genetic analysis for pancreatic cancers.
We have been carrying out active surveillance for FPC through epidemiological surveys, imaging analyses, and
genetic analysis.
Case presentation: Here, we present the case of a female patient harboring pathogenic variants of PALB2 and
NBN, with a family history of multiple pancreatic cancer in her younger brother, her aunt, and her father. Moreover,
her father harbored a PALB2 pathogenic variant and her daughter harbored the same NBN pathogenic variant.
Given the PALB2 and NBN variants, we designed surveillance strategies for the pancreas, breast, and ovary.
Conclusions: Further studies are required to develop strategies for managing FPCs to facilitate prompt diagnosis
before their progression.
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Background
Pancreatic cancer is one of the most lethal malignant
diseases, despite the development of medical technology,
including surgical skills and anticancer drugs. Moreover,
it is difficult to detect pancreatic cancer through clinical
examination due to the absence of novel biomarkers.
Numerous recent studies have reported that some pan-
creatic cancers have hereditary factors and germline var-
iants, especially in DNA repair genes. This is similar to
the mechanism of hereditary breast and ovarian cancer
(HBOC) syndrome caused by the BRCA1/2 germline
variant. In the National Clinical Cancer Network
(NCCN) guidelines, revised in 2020, familial pancreatic
cancer (FPC) was included in the HBOC syndrome be-
cause FPC harbors BRCA1/2 germline variants to some
extent [1]. Furthermore, recent studies have reported
that BRCA1/2 pathogenic variants potentially contribute
to FPC and that the frequency of BRCA1/2, PALB2, and
ATM variants in all pancreatic cancers is 7% [2–4].
Here, we report a pedigree with a lineage of strongly
suspected FPC, resulting from PALB2 and NBN patho-
genic variants. PALB2, a partner and localizer of BRCA2,
is a Fanconi anemia group protein (FANCN), which per-
mits stable intranuclear localization and accumulation of
BRCA2 and can cause pancreatic, breast, and ovarian
cancer [5]. To our knowledge, this is the first reported
case of a Japanese pedigree harboring both PALB2 and
NBN variants. Furthermore, this study describes a
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literature review on the latest reports and management
strategies related to FPC.
Case presentation
A 49-year-old woman at first consultation presented at
our hospital for surveillance of the pancreas because her
father (II-3) and her younger brother (III-6) had pancre-
atic cancer. She had undergone surgery for subarachnoid
hemorrhage at 19 years of age because of an arterioven-
ous malformation. Her family tree (Fig. 1) revealed that
her younger brother died of pancreatic cancer at 33 years
of age; he could not be treated through surgery because
of his advanced stage with distant metastasis. The pa-
tient’s paternal aunt (II-1) also died of pancreatic cancer
at 65 years of age. Her father was also diagnosed with
advanced-stage pancreatic cancer, which could not be
controlled despite chemotherapy.
In the first genetic counseling session, the patient was
informed that she was likely to have FPC, Lynch syn-
drome, or HBOC syndrome, all of which follow an auto-
somal dominant inheritance pattern. Therefore, germline
multi-gene panel testing using ACTRisk® (ACT Genomics,
Co. Ltd. Taipei, Taiwan) was performed to analyze germ-
line variants in this case.
In the second genetic counseling session, we informed
her that the blood genetic test revealed two germline vari-
ants. She harbored a heterozygous PALB2 pathogenic vari-
ant, NM_024675(PALB2): c.1675_1676inv (p.Gln559*),
and a heterozygous NBN pathogenic variant, NM_
002485(NBN): c.265C > T (p.Arg89*). These variants are
predicted to cause loss of normal protein function through
either protein truncation or nonsense-mediated mRNA
decay. Therefore, we advised her to undergo surveillance
for breast, ovarian, and pancreatic cancer. Her father died
9 months after her first consultation; however, he had pre-
viously provided a blood sample to our department before
his death to support her future healthcare. Accordingly,
genetic testing of her father’s blood sample was recom-
mended to her.
In the third genetic counseling session, we explained
that her father’s blood revealed the presence of the
PALB2 c.1675_1676inv (p.Gln559) pathogenic variant,
which was the same as hers. Furthermore, we informed
her that her first-degree relatives (FDR) have a 50%
chance of testing positive for these variants. Therefore,
we recommended genetic counseling for her children at
the next session, and she agreed.
In the fourth genetic counseling session, the patient
and her three children, a 28-year-old woman, a 24-year-
old man, and a 22-year-old man, presented at our out-
patient department. We explained to them that their
mother and her father harbored the PALB2 pathogenic
variant, which was probably associated with breast, ovar-
ian, pancreatic, and prostate cancer. Furthermore, we in-
formed them that their mother harbored the NBN
pathogenic variant, which was potentially associated with
breast, ovarian, and pancreatic cancer. Upon surveil-
lance, no issue was noted in the cases’s breasts and ovar-
ies; however, she displayed a branch duct type
intraductal papillary mucinous neoplasm (BD-IPMN) in
her pancreas. We suggested she continue active surveil-
lance of her breasts, ovaries, and pancreas. Furthermore,
Fig. 1 Family history of the pedigree. I-1: Dead from lung cancer at 69 years of age. I-2: Dead from endometrial cancer at 40 years of age. II-2:
Dead from pancreatic cancer when she was 65 years of age. II-3: Dead from gastric cancer at 49 years of age. II-5: Diagnosed with unresectable
pancreatic cancer after his son died. After the first genetic counseling, he underwent chemotherapy for cancer but died at 75 years of age. III-5:
The PALB2/NBN pathogenic variants and branch-duct type IPMN. She has three children; a 28-year-old daughter (IV-3), a 24-year-old son (IV-4),
and a 22-year-old son (IV-5). III-6: Diagnosed with advanced pancreatic adenocarcinoma at 32 years of age. He passed away despite undergoing
chemotherapy for 10 months. IV-3: The NBN pathogenic variant
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her 28-year-old daughter wished to undergo genetic test-
ing because her uncle had died from pancreatic cancer
at an early age. Therefore, we performed genetic testing
at a single site for the patient’s daughter. Finally, the pa-
tient’s daughter underwent genetic counseling and was
found to harbor only the NBN c.265C > T(p.Arg89*)
pathogenic variant, which was probably associated with
breast, ovarian, pancreatic cancer. Thus, the daughter
will be recommended to undergo surveillance for breast,
ovarian, and pancreatic cancer.
Discussion and conclusions
We reported a pedigree with FPC, harboring a PALB2
pathogenic variant. Based on family history, the patient’s
father and younger brother and her father’s sister had
pancreatic cancer, whereas her mother’s family did not
have a cancer history. Thus, her PALB2 variant was
inherited from her father, as revealed through genetic
analysis. Furthermore, she had BD-IPMN, which can de-
velop into pancreatic cancer. BD-IPMN cases are report-
edly at a lower risk of pancreatic cancer than those with
main-duct-type IPMN or mixed-type IPMN; however,
invasive pancreatic cancer has reportedly occurred in ap-
proximately 3.8% of BD-IPMN cases after 84 months
follow-up [6]. Hence, we intend to follow the present
case annually using magnetic resonance imaging (MRI)
or endoscopic ultrasound (EUS) imaging. Furthermore,
the patient and her daughter harbored the NBN patho-
genic variant, which reportedly elevates the risk of
breast, ovarian, and pancreatic cancer.
A case of FPC was first reported in 1976 in a patient
presenting multiple instances of pancreatic cancer in
their family history [7]. The FPC registry was first devel-
oped at Johns Hopkins University in the United States in
1994. The Japanese Familial Pancreatic Cancer Registry
(JFPCR) was established in 2014; it serves to recruit pa-
tients with pancreatic tumors and their first- and
second-degree relatives. Furthermore, the JFPCR pro-
vides information regarding a patient’s family history
and lifestyle [8, 9] but does not include germline variants
[8, 9]. Germline variants of FPC have been reported at
various institutes, and the most common germline vari-
ant is the DNA repair gene family, including BRCA1/2,
ATM, PALB2, CHEK2, and RAD51 [10].
The BRCA2 variant is more frequent (approximately
4–17%) among patients with FPC than is BRCA1, and
the PALB2 variant has been observed in 2–3% of cases
[11]. PALB2, which encodes a BRCA2-interacting pro-
tein, was first reported as a breast cancer susceptibility
gene in 2007 [12]. Biallelic PALB2 variants are respon-
sible for a subset of Fanconi anemia cases characterized
by a phenotype similar to that caused by biallelic
BRCA1/2 variants [13]. Most patients with FPC and
HBOC syndrome harbor monoallelic PALB2 or BRCA1/
2 variants, which follow an autosomal dominant inherit-
ance pattern [13].
NBN, discovered as a cause of Nijmegan breakage syn-
drome through biallelic pathogenic variants, is a type of
DNA damage response gene that is associated with se-
vere microcephaly, infertility, and cancer risk [14]. The
95-kDa NBN protein has 754 amino acid residues and is
a component of the MRN complex comprising MRE11,
RAD50, and NBN. The MRN complex is one of the first
players to detect double-stranded breaks and be re-
cruited to chromatin through interactions between poly-
ADP-ribose (PAR) and its first BRCT domain [15]. NBN
is potentially susceptible to variation in breast and ovar-
ian cancers [16]; however, this pathogenic variant is less
known than BRCA1/2, ATM, or PALB2. Moreover, re-
cent studies have reported that the NBN variant is asso-
ciated with pancreatic cancer [17, 18]. In our case, the
NBN variant may have been inherited from her mother’s
lineage or may have originated de novo, although no
studies have reported de novo NBN variants. The pa-
tient’s daughter harbored the same NBN variant; hence,
continued surveillance of the breast, ovary, and pancreas
is needed.
One of the most important considerations from this
case is determining how we should perform cancer sur-
veillance for unaffected family members who harbor
germline variants. HBOC is the most frequent hereditary
tumor, and management guidelines have been estab-
lished worldwide; however, no standardized surveillance
methods are available for FPC. Furthermore, no guide-
lines for non-BRCA1/2 HBOC are available in Japan,
despite the increasing number of non-BRCA1/2 HBOC
cases. To resolve these issues, surveillance for FPC and
management guidelines for HBOC and FPC should be
considered as soon as possible.
According to the report from the evidence-based net-
work for the interpretation of germline mutant alleles
(ENGIMA) clinical working group, breast cancer surveil-
lance for PALB2 is different across countries [19]. For
example, the United States, France, Spain, Australia, and
Germany recommend an annual mammogram and
breast MRI from the age of 30 years and consider re-
duced risk mastectomy (RRM), whereas Belgium, the
United Kingdom, and Japan have no guidelines regard-
ing PALB2 management. The guideline regarding NBN
surveillance in the United States is for individuals with
the NBN variant to undergo mammograms and breast
MRIs from the age of 40 years. The Japanese manage-
ment of non-BRCA1/2 pathogenic variants, including
PALB2, ATM, and NBN, should be concreated because
non-BRCA1/2 genes are greatly associated with heredi-
tary pancreatic cancer.
Our institute performs pancreatic cancer surveillance
for cases with germline variants in accordance with the
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International Cancer of Pancreas Screening (CAPS)
established in 2013 by Johns Hopkins University [20].
We denote the following as high-risk individuals (HRI):
persons with three or more blood relatives with pancre-
atic cancer, those with at least two affected FDRs, pa-
tients with Peutz-Jeghers syndrome, and those who
already harbor germline variants in BRCA1/2, PALB2,
ATM, CDKN2A, MLH1, MSH2, MSH6, EPCAM, STK11,
and TP53. We then perform abdominal MRIs for HRI
and, if they have no issue in the pancreas, we recom-
mend an annual abdominal MRI. If they have issues in
the pancreas, we perform endoscopic ultrasound (EUS).
This surveillance has been recommended in accordance
with the NCCN guidelines 2020 Ver1 [1]. Accordingly,
the patient and her daughter in this case study need to
undergo breast, ovary, and pancreatic cancer surveil-
lance, and the her two sons need to undergo genetic
counseling.
In conclusion, we reported a family with hereditary
pancreatic cancer harboring pathogenic variants of both
PALB2 and NBN. The PALB2 pathogenic variant in our
case was inherited from her father, and her NBN patho-
genic variant was inherited by her daughter. This case
indicated that we should share and generalize our know-
ledge and perform active surveillance of HRIs for pan-
creatic cancer. Furthermore, a prospective cohort study
and registration system, including gene variants to estab-
lish national or international guidelines, is required. In
conclusion, an increased number of studies on FPC
would help establish management guidelines for the sur-
veillance or screening of pancreatic cancer to detect
early-stage cancer and improve prognosis.
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